Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call?

Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call?

Disclosure: I own shares of AMGN and GILD

Biotechnology stocks have been in a sharp correction this week. The iShares Nasdaq Biotechnology ETF dropped close to one-percent in early Thursday trade, following a 1.89% decline on Wednesday; and the SPDR S&P biotech ETF registered similar losses.

Is the correction a buying opportunity or a wake up call?

Both.

On the one side, the correction is a buying opportunity for biotech companies with sound fundamentals. That is, companies which have a broad portfolio of products that have pasted both the lab test and the market test, and delivered the “milk,” ie profits on Wall Street.

Gilead Sciences is one of these companies, which has close to $25 billions in revenues and trades at a forward PE of less than 10. Amgen and Regeneron Pharmaceuticals have solid revenues, though they trade at higher–but reasonable for a fast growing sector–PEs.

That’s how biotechnology investing has turned into a hot theme in the mass and social media.

Company

Market Cap

Forward PE

Revenues

Operating Margins

Gilead Sciences

149.39B

9.72*

24.89B

62.82%

Regeneron Pharmaceuticals

43.17B

35.51*

2.82B

29.74

Amgen

116.45B

15.23*

20.06B

34.21

*Fye Dec 31, 2016

Source: Finance.yahoo.com

On the other side, the correction is a wake up call for companies with shaky fundamentals. That is, companies which have reached a market valuation of many billions of dollars, though they have little or no product revenues.

Puma Biotechnology, for instance, has a market capitalization north of $7 billion, though it has no revenue. Intercept Pharmaceuticals has a Market cap to revenue ratio of 372.41, and Isis Pharmaceuticals has somewhat better ratios.

Company

Market Capitalization

Revenues

Market Cap/Revenues

Puma Biotechnology

6.96B

Intercept Pharmaceuticals

5.80B

1.74M

372.41

Isis Pharmaceuticals

7.21B

214.16M

38.31

Source: Finance.yahoo.com

That’s why I would rather stay with the first sector rather than chase after the second sector.

Excerpt from: 

Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call?

See which stocks are being affected by Social Media

Share this post

Comments (0)